Prexa Pharmaceuticals
Prexa Pharmaceuticals develops small molecule monoamine reuptake inhibitors as a treatment for ADHD, depression and Parkinson’s disease.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD38—57m (Dealroom.co estimates May 2011.)
Boston Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$7.0m | Series B | ||
| Total Funding | CAD9.5m | ||